{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:45:17Z","timestamp":1781153117328,"version":"3.54.1"},"reference-count":50,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The survival rate of multiple myeloma (MM) patients has drastically increased recently as a result of the wide treatment options now available. Younger patients truly benefit from these innovations as they can support more intensive treatment, such as autologous stem cell transplant or multiple drug association (triplet, quadruplet). The emergence of immunotherapy allowed new combinations principally based on monoclonal anti-CD38 antibodies for these patients. Still, the optimal induction treatment has not been found yet. While consolidation is still debated, maintenance treatment is now well acknowledged to prolong survival. Lenalidomide monotherapy is the only drug approved in that setting, but many innovations are expected. Older patients, now logically named not transplant-eligible, also took advantage of these breakthrough innovations as most of the recent drugs have a more acceptable safety profile than previous cytotoxic agents. For this heterogenous subgroup, geriatric assessment has become an essential tool to identify frail patients and provide tailored strategies. At relapse, options are now numerous, especially for patients who were not treated with lenalidomide, or not refractory at least. Concerning lenalidomide refractory patients, approved combinations are lacking, but many trials are ongoing to fill that space. Moreover, innovative therapeutics are increasingly being developed with modern immunotherapy, such as chimeric antigen receptor T-cells (CAR-T cells), bispecific antibodies, or antibody\u2013drug conjugates. For now, these treatments are usually reserved to heavily pre-treated patients with a poor outcome. MM drug classes have tremendously extended from historical alkylating agents to current dominant associations with proteasome inhibitors, immunomodulatory agents, and monoclonal anti-CD38\/anti SLAMF7 antibodies. Plus, in only a couple of years, several new classes will enter the MM armamentarium, such as cereblon E3 ligase modulators (CELMoDs), selective inhibitors of nuclear export, and peptide\u2013drug conjugates. Among the questions that will need to be answered in the years to come is the position of these new treatments in the therapeutic strategy, as well as the role of minimal residual disease-driven strategies which will be a key issue to elucidate. Through this review, we chose to enumerate and comment on the most recent advances in MM therapeutics which have undergone major transformations over the past decade.<\/jats:p>","DOI":"10.3390\/cancers12102885","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T08:52:41Z","timestamp":1602147161000},"page":"2885","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020"],"prefix":"10.3390","volume":"12","author":[{"given":"Arthur","family":"Bobin","sequence":"first","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Liuu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Moya","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Gruchet","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Sabirou","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"L\u00e9vy","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Gardeney","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laly","family":"Nsiala","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cailly","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tomowiak","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Systchenko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ch\u00e2tellerault Hospital Center, 1 rue du Dr Luc Montagnier, 86106 Ch\u00e2tellerault, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Javaugue","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Durand","sequence":"additional","affiliation":[{"name":"Department of Rhumatology, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5639-0138","authenticated-orcid":false,"given":"Mathieu","family":"Puyade","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, and CIC1402 INSERM unit, Poitiers University Hospital, 2 Rue de la Mil\u00e9trie, 86021 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study","volume":"18","author":"Mohty","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2018-99-112659","article-title":"Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma","volume":"132","author":"Hebraud","year":"2018","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2019-123170","article-title":"Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myelo","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial","volume":"37","author":"Gay","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology study","volume":"20","author":"Repetto","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/bjh.16194","article-title":"A novel Haemato-oncology Frailty (HOF) score tool predicts survival in over 80s with Multiple Myeloma","volume":"187","author":"Hinton","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): A development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: An overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA3","article-title":"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial","volume":"38","author":"Kumar","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2019-123426","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia","volume":"134","author":"Bahlis","year":"2019","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2019-123483","article-title":"Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Kaufman","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"ASPIRE Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma - PROTOCOL","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (relapsed\/refractory)","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood-2019-132629","article-title":"Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor NCT03158688","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon-2017-0616","article-title":"Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA Phase III study design","volume":"14","author":"Richardson","year":"2018","journal-title":"Futur. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): A multicentre, international, open-label, phase 1\u20132 study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.clml.2019.09.046","article-title":"A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"19","author":"Kumar","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed\/Refractory Multiple","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: A Phase 1b\/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and\/or Refractory Multiple Myeloma (R\/R MM)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2019-131373","article-title":"FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma","volume":"134","author":"Bjordahl","year":"2019","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","article-title":"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study","volume":"37","author":"Topp","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2885\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:17:25Z","timestamp":1760177845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["cancers12102885"],"URL":"https:\/\/doi.org\/10.3390\/cancers12102885","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]}}}